Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer

被引:0
作者
N Larochelle
H Lochmüller
J Zhao
A Jani
P Hallauer
KEM Hastings
B Massie
S Prescott
BJ Petrof
G Karpati
J Nalbantoglu
机构
[1] Neuromuscular Research Group,Respiratory Division
[2] Montreal Neurological Institute,undefined
[3] Biotechnology Research Institute,undefined
[4] National Council of Canada,undefined
[5] Royal Victoria Hospital,undefined
[6] and Meakins-Christie Laboratories,undefined
[7] McGill University,undefined
[8] Genzentrum,undefined
[9] Institut für Biochemie,undefined
[10] Ludwig-Maximilians Universitat,undefined
来源
Gene Therapy | 1997年 / 4卷
关键词
muscle creatine kinase; promoter; adenovirus; gene therapy; muscle-specific expression;
D O I
暂无
中图分类号
学科分类号
摘要
Replication-defective (E1+E3-deleted) human adenovirus vectors are a promising means of therapeutic gene delivery to skeletal muscle cells. Since the tropism of adenovirus is nonselective, muscle-specific expression of systemically administered vectors can only be achieved by the use of a tissue-specific promoter/enhancer that is small enough to fit the insert capacity of the vector. We have generated two replication-defective adenovirus recombinants (AV) in which the reporter gene (either firefly luciferase or E. coli β-galactosidase) was driven by a truncated (1.35 kb) muscle creatine kinase (MCK) promoter/enhancer or by the fast troponin I (TnI) promoter/enhancer. Highly efficient and muscle-specific transgene expression was demonstrated in immunodeficient mice after local injection of AV into muscles at an early age. In nonmuscle tissues (brain, liver, kidney, lung), the transgene expression was extremely low even though in these tissues in situ polymerase chain reaction showed as high an infectivity of the cells by the AV as in muscle. The relatively small size, the good efficiency and the muscle specificity of the MCK promoter would make it ideal to drive the 6.3 kb (truncated) dystrophin cDNA in first generation AV (with a limited (8 kb) insert capacity) designed for gene therapy of Duchenne muscular dystrophy.
引用
收藏
页码:465 / 472
页数:7
相关论文
empty
未找到相关数据